Association of epilepsy and asthma: A population-based retrospective cohort study

Kuo-Liang Chiang Corresp., 1, 2, 3, Fang-Chuan Kuo 4, Jen-Yu Lee 5, Chin-Yin Huang 6

1 Department of Pediatric Neurology, Kuang-Tien General Hospital, Taichung, Taiwan
2 Department of Nutrition, Hungkuang University, Taichung, Taiwan
3 Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung, Taiwan
4 Department of Physical Therapy, Hungkuang University, Taichung, Taiwan
5 Department of Statistics, Feng Chia University, Taichung, Taiwan
6 Program for Health Administration, Tunghai University, Taichung, Taiwan

Corresponding Author: Kuo-Liang Chiang
Email address: lambier.tw@yahoo.com.tw

Background. Epidemiologic data supporting the epilepsy-asthma association are insufficient. Therefore, we examined this association in this study.

Methods. By using claims data from the National Health Insurance Research Database (Taiwan), we executed a retrospective cohort analysis. Analysis 1 entailed comparing 150,827 patients diagnosed as having incident asthma during 1996-2013 with disease-free controls who were selected randomly during the same period, frequency matched in terms of age and sex. Similarly, analysis 2 entailed comparing 25,274 patients newly diagnosed as having epilepsy with sex- and age-matched controls who were selected randomly. At the end of 2013, we evaluated in analysis 1 the epilepsy incidence and risk and evaluated in analysis 2 the asthma incidence and risk. We applied Kaplan–Meier analysis to derive plots of the proportion of asthma-free seizures.

Results. In analysis 1, the asthma group exhibited a higher epilepsy incidence than did the control group (3.05 versus 2.26 per 1,000 person-years; adjusted hazard ratio: 1.39, 95% confidence interval: 1.33–1.45). We also noted a greater risk of subsequent epilepsy in women and girls. In analysis 2, we determined that the asthma incidence between the control and epilepsy groups did not differ significantly; however, some age subgroups including children and individuals in their 30s had an increased risk. A negative association was found in adolescents. The Kaplan–Meier analysis revealed epilepsy to be positively associated with subsequent onset of asthma within 7 years of epilepsy diagnosis.

Discussion. Asthma may be associated with high epilepsy risk, and epilepsy may be associated with high asthma risk among children and individuals in their 30s. Nevertheless, people with epilepsy in other age subgroups should be aware of the possibility of developing asthma within 7 years of epilepsy diagnosis.
Association of epilepsy with asthma: A population-based retrospective cohort study

Kuo-Liang Chiang\textsuperscript{1,2,3,*}, Fang-Chuan Kuo\textsuperscript{4}, Jen-Yu Lee\textsuperscript{5,*} and Chin-Yin Huang\textsuperscript{6}

\textsuperscript{1}Department of Pediatric Neurology, Kuang-Tien General Hospital, Taichung, Taiwan

\textsuperscript{2}Department of Nutrition, Hungkuang University, Taichung, Taiwan

\textsuperscript{3}Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung, Taiwan

\textsuperscript{4}Department of Physical Therapy, Hungkuang University, Taichung, Taiwan

\textsuperscript{5}Department of Statistics, Feng Chia University, Taichung, Taiwan

\textsuperscript{6}Program for Health Administration, Tunghai University, Taichung, Taiwan

Corresponding Author:

Kuo-Liang Chiang\textsuperscript{1}

No.117, Shatian Road Shalu District, Taichung City 433, Taiwan

E-mail:

*These authors contributed equally to this work.

Data available statement:

Data are available from the National Health Insurance Research Database (NHIRD) published by Taiwan
National Health Insurance (NHI) Bureau. The data utilized in this study cannot be made available in the paper, the supplemental files, or in a public repository due to the "Personal Information Protection Act" executed by Taiwan's government, starting from 2012. Requests for data can be sent as a formal proposal to the NHIRD (http://nhird.nhri.org.tw) or by email to nhird@nhri.org.tw.
ABSTRACT

Background. Epidemiologic data supporting the epilepsy–asthma association are insufficient. Therefore, we examined this association in this study.

Methods. By using claims data from the National Health Insurance Research Database (Taiwan), we executed a retrospective cohort analysis. Analysis 1 entailed comparing 150,827 patients diagnosed as having incident asthma during 1996–2013 with disease-free controls who were selected randomly during the same period, frequency matched in terms of age and sex. Similarly, analysis 2 entailed comparing 25,274 patients newly diagnosed as having epilepsy with sex- and age-matched controls who were selected randomly. At the end of 2013, we evaluated in analysis 1 the epilepsy incidence and risk and evaluated in analysis 2 the asthma incidence and risk. We applied Kaplan–Meier analysis to derive plots of the proportion of asthma-free seizures.

Results. In analysis 1, the asthma group exhibited a higher epilepsy incidence than did the control group (3.05 versus 2.26 per 1,000 person-years; adjusted hazard ratio: 1.39, 95% confidence interval: 1.33–1.45). We also noted a greater risk of subsequent epilepsy in women and girls. In analysis 2, we determined that the asthma incidence between the control and epilepsy groups did not differ significantly; however, some age subgroups including children and individuals in their 30s had an increased risk. A negative association was found in adolescents. The Kaplan–Meier analysis revealed epilepsy to be positively associated with subsequent onset of asthma within 7 years of epilepsy diagnosis.

Discussion. Asthma may be associated with high epilepsy risk, and epilepsy may be associated with high asthma risk among children and individuals in their 30s. Nevertheless, people with epilepsy in other age subgroups should be aware of the possibility of developing asthma within 7
44 years of epilepsy diagnosis.
INTRODUCTION

Asthma and epilepsy are syndromes of heterogeneous diseases with likely multifactorial origins. Epilepsy, a ubiquitous neurological disease, is characterized by the occurrence of convulsive and nonconvulsive seizures. Estimates have revealed that epilepsy affects more than 50 million people worldwide, including 2 million people in the United States (Browne & Holmes, 2001; Chang & Lowenstein, 2003), and Moreover, asthma, a ubiquitous chronic disease, inherently involves changing degrees of airflow obstruction and airway inflammation as well as coughing, wheezing, and dyspnea episodes. Asthma has been estimated to affect over 300 million people worldwide, including 20 million people in the United States (Masoli et al., 2004; Olin & Wechsler, 2014). In Taiwan, the age-adjusted prevalence of epilepsy was 5.85 (per 1000) between 2000 and 2003 (Chen et al., 2012); the period prevalence of asthma was 11.9% between 2000 and 2007 (Hwang et al., 2010). Asthma and epilepsy are common causes of acute hospitalization. In the United States, epilepsy or convulsions make up 1% of all visits to the emergency department (ED) annually, and epilepsy uniformly constitutes 3.6% of all hospital admissions and admission rates across the country (Pallin et al., 2008; Stump, 2008). In the United States, acute asthma constitutes approximately 2% of all ED visits and 1.3% of all annual hospitalizations (Moorman et al., 2007). The annual global burden due to 23.4 million individuals with epilepsy in 2015 was estimated to be 12.4 million disability-adjusted life years (DALYs) (Feigin et al., 2017); 358.2 million individuals with asthma caused 26.2 million DALYs (Soriano et al., 2017). Thus, epilepsy and asthma are cost-intensive, complicated global health concerns (England et al., 2012; Pawankar, 2014; Nunes, Pereira & Morais-Almeida, 2017) that tend to reduce patients’ quality of life (Wang et al., 2012) and place a considerable burden on their family members.
Asthma is associated with multiple neuropsychiatric disorders in children and adults, some of which are anxiety, attention deficit hyperactivity disorder, autism, and depression (Fasmer et al., 2011; Van Lieshout & Macqueen, 2012; Brumpton et al., 2013; Oh et al., 2015; Zheng et al., 2016, Choi et al., 2017). However, the association of epilepsy with asthma has never been clarified. Questions such as whether epilepsy can manifest as a bronchial spasm in asthma pathogenesis and whether people with asthma are more likely to develop epilepsy remain to be resolved. Immunity and inflammation seem to play a role in both disorders, with a sufficient body of experimental and clinical evidence suggesting that brain inflammation has the likelihood of predisposing a patient to and precipitating and perpetuating epileptogenesis. Certain systemic and neurological autoimmune disorders are reportedly affiliated with epilepsy, such as lupus cerebritis, Hashimoto’s encephalopathy, multiple sclerosis, Rasmussen’s encephalitis, linear scleroderma, and anti-N-methyl-D-aspartate receptor encephalitis (Chiang et al., 2009a; Chiang et al., 2009b; Vincent & Crino, 2011; Devinsky, Schein & Najjar, 2013). Proinflammatory cytokines play neuromodulatory functions, in addition to contributing to aberrant neuronal excitability underlying seizure disorders. Epilepsy and asthma share excitatory factors such as voltage-gated sodium channels, glutamate (i.e., N-methyl-D-aspartic acid), and acetylcholine, as well as inhibitory factors such as voltage-gated potassium channels, γ-aminobutyric acid (gamma-aminobutyric acid [GABA]), glycine, and taurine. One study proposed a pathogenetic mechanism of asthma, similar to that of epilepsy, as a syndrome pertaining to genetically predisposed or inducible membrane hyperexcitability (Hoang et al., 2006). These findings imply a complex association between the two disorders.

Researchers have attempted for numerous decades to link epilepsy to asthma. Studies published prior to 1970 (Levin, 1931; Forman, 1934; Speer, 1967; Fein & Kamin, 1968) have
hypothesized patients with asthma and other allergy conditions to be highly likely to experience seizures (and vice versa). The mentioned studies have applied terms that include “neurologic allergy” and “allergic epilepsy” to report allergies, concurrently presenting asthma, and epilepsy. Furthermore, some studies executed after 1970 have established a link between asthma and epilepsy based on electroencephalographic findings (Mysik & Czerniawska-Mysik, 1972; Cinca and Dimitriu, 1976; Abramson, 1978). However, despite growing bodies of evidence revealing such an association, only a few epidemiologic studies have been conducted on this association (Castaneda et al., 1998; Kobau et al., 2004; Strine et al., 2005; Bilan, 2008; Elliott, Moore & Lu, 2008; Silverberg, Joks & Durkin, 2014), all of which had small sample sizes or used a cross-sectional design. Our review of the relevant literature showed that studies have yet to focus on this problem in Asian countries. In summary, large longitudinal studies in various populations are required to definitively explore the association between these two disorders and fill the knowledge gap.

In 1995, Taiwan implemented its National Health Insurance (NHI) program, which provides coverage for affordable, equitable, and universal health care to over 98% of Taiwan’s 26 million residents (Chien et al., 2012). Similar to a natural laboratory setting, the NHI program’s comprehensive health care coverage and continuous observation provide a special opportunity for the long-term observation of the correlation between epilepsy and asthma. Accordingly, in the present study, we utilized a longitudinal dataset from the National Health Insurance Research Database (NHIRD) and employed a large sample and representative data to execute a two-way population-based retrospective analysis in order to evaluate the asthma risk among patients with epilepsy as well as the epilepsy risk among patients with asthma.
MATERIALS AND METHODS

Data source

The data we used were subset data of the NHIRD, a database of longitudinal claims data covering a cohort of 1 million people randomly selected from among all of the insured NHI beneficiaries. Annually, the National Health Insurance Administration (NHIA) compiles NHI data and then arranges the data as data files (e.g., registration data and original claims data), to process reimbursements. For privacy protection, the files are deidentified through the scrambling of patient and medical facility identification codes and are subsequently dispatched to the National Health Research Institutes (NHRI), thus forming the original data files of the NHIRD.

We employed three types of data files—namely the ambulatory care claims, inpatient claims, and registry of beneficiaries—that are linked using an encrypted yet distinctive personal identification number. The files contain patient data regarding medical history and demographic characteristics. Identifiers for individuals and medical facilities are unique to the NHIRD and researchers, and they cannot be applied to trace patients or providers of health services. Therefore, the requirement for full review was waived by the Institutional Review Board of Kuang Tien General Hospital, and the use of these data was authorized by the NHRI.

Study design and patients

We evaluated the bidirectional epilepsy–asthma association by performing two analyses. In both analyses, we used the same procedures for selecting the patients (Fig. 1). Specifically, for analysis 1, we discovered patients with asthma [International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 493] (i.e., the asthma group) and established a
control group comprising individuals without asthma. For analysis 2, we discovered patients with epilepsy (ICD-9-CM code 345) (i.e., the epilepsy group) and established a control group comprising individuals without epilepsy. In analyses 1 and 2, we assigned to the patient groups patients who had had inpatient claim or an initial ambulatory claim for asthma (analysis 1) or epilepsy (analysis 2) during 1996–2013. For each patient, the diagnosis date was defined to be the index date. The control groups were matched with the asthma (analysis 1) and epilepsy (analysis 2) groups during the study period. We applied a 1:1 control-to-case ratio. To investigate the temporal association of asthma with the subsequent occurrence of epilepsy, we excluded from analysis 1 patients who had been diagnosed as having epilepsy before receiving a diagnosis of asthma. Similarly, we excluded from analysis 2 patients who had been diagnosed as having asthma before epilepsy. We followed up all patients to determine the epilepsy or asthma incidence (analysis 1 and 2, respectively) until December 31, 2013, or their withdrawal from NHI coverage.

Statistical analysis

The R Project for Statistical Computing (version 3.25) was used for all statistical analyses. In both analyses, we compared the differences in the categorical and continuous variables in the demographic data of the controls and patients by employing the chi-squared test and the independent-sample t test, respectively. Sex, age, household income, and residence location were analyzed. We stratified age into eight bands: 0–10, 11–20, 21–30, 31–40, 41–50, 51–60, 61–70, and >70 years. In addition, studies have reported that low socioeconomic status and low incomes are key risk factors not only for epilepsy (Heaney et al., 2002; Kaiboriboon et al., 2013) but also for the prevalence of asthma and increasing hospitalization due to asthma (Ray et al., 1998; Markus et al., 2010). Thus, we employed household income as a confounding variable. We
divided household income levels into four categories in terms of insurance premiums: >40,000NT$, 20,000–39,999NT$, 1–19,999NT$, and dependents. The NHIA and government consider individuals who do not receive a salary, such as unemployed people, students, and elderly people, as dependents. Similar to previous studies using NHIRD data, we classified residence location into the following regions of Taiwan: northern, central, southern, and eastern (Chie et al., 1995; Lu et al., 2006; Chen et al., 2012). Geographical variation, a demographic factor, refers to differences among populations of a species in terms of genetic-based traits across the natural geographic range of the species. Compared with other regions, northern Taiwan comprises a higher number of economically and politically important cities, whereas eastern Taiwan comprises less politico-economic importance and a different demographic structure, with more indigenous people and a lower population density. One study reported geographic variation in epidemiologic patterns of epilepsy within Taiwan; eastern Taiwan had significantly higher prevalence and incidence of epilepsy than did other areas (Chen et al., 2012). Geographic variation also reported epidemiologic patterns of asthma in other countries (Carvajal-Uruena et al., 2005, Malhotra et al., 2014).

We assessed in analysis 1 the overall as well as sex-specific epilepsy incidence for patients with asthma and their corresponding controls. By applying Cox proportional hazard regression models, we estimated the hazard ratios (HRs) associated with epilepsy development in patients with asthma relative to that in the control group. Geographical variation and household income were adjusted for in the multivariate models. In addition, we applied Kaplan–Meier analysis to derive plots of the proportion of seizure-free asthma. We used the same data analysis procedures in both analyses. In analysis 2, we applied similar Cox regression models to evaluate the HRs associated with asthma incidence in patients with epilepsy relative to that in the control group.
For both sets of analyses, we set statistical significance at ≤0.05. Additionally, we employed Kaplan–Meier analysis to derive plots of the proportion of asthma-free seizures.
RESULTS

Asthma and risk of developing epilepsy

In the 1996–2013 data, we discovered 150,827 patients with asthma and 150,827 age- and sex-matched controls (Table 1); among these patients, 31.42% were aged 0–10 years and 51.05% were female patients. Household income data were similar between the two groups. Patients with asthma were indicated to be more likely to reside or work in northern Taiwan, compared with the controls (52.01% versus 45.24%). We observed the median follow-up periods in the asthma and control groups to be 5.8 and 6.2 years, respectively.

The asthma group exhibited a higher epilepsy incidence (3.05 versus 2.26 per 1,000 person-years; see Table 2). As revealed by the regression model, patients with asthma were 1.39 times more likely to develop epilepsy [95% confidence interval (CI) 1.33–1.45] after age, sex, income, and residence location had been controlled for. In both groups, the epilepsy incidence was higher in boys and men than it was in girls and women (Table 2). An association between asthma and increased epilepsy incidence was observed in both sexes, with a significantly higher relative risk estimate (t test) in girls and women (adjusted HR: 1.52, 95% CI: 1.42–1.64) than in boys and men (adjusted HR: 1.28, 95% CI: 1.21–1.37). In addition, the epilepsy and control groups both had lower subsequent incidence of asthma in patients among the highest household income bracket (>NT$40,000); among patients who lived in eastern Taiwan, both groups also had higher subsequent incidence of asthma.

The Kaplan–Meier analysis results revealed a consistent positive association between asthma and subsequent epilepsy development (Fig. 2).
Epilepsy and corresponding risk of asthma

In the 1996–2013 data, we identified 25,274 patients with epilepsy and 25,274 age-matched and sex-matched controls (Table 3); among these patients, 20.3% were aged <10 years, 14.2% were aged >70 years, and 9.2%–12.8% were in each of the other age groups, and 45.5% were also female patients. We observed epilepsy group to be more likely to have a lower household income, compared with the control group (dependent—lowest income level: 18.9% versus 24.3%). Moreover, patients with epilepsy were found to be more likely to reside or work in northern Taiwan than were their controls (45.3% versus 42.8%). We noted the median follow-up periods in the epilepsy and control groups to be 6.1 and 6.4 years, respectively.

Although the epilepsy group exhibited a higher asthma incidence than did the control group (18.79 versus 17.75 per 1,000 person-years; Table 4), the regression model did not provide supportive evidence (adjusted HR: 0.96, 95% CI: 0.91–0.999) after age, sex, income, and residence location had been controlled for. Although the results indicated a significant negative association, only mild influence was observed. A similar result was observed for male patients with epilepsy versus male individuals without epilepsy (adjusted HR: 0.91, 95% CI: 0.86–0.97).

However, we observed a positive association in some age subgroups, including people aged 0–10 and 31–40 years. In the 0–10-year subgroup, the epilepsy group exhibited a higher asthma incidence than did the control group (36.43 versus 33.85 per 1,000 person-years; adjusted HR: 1.09, 95% CI: 1.01–1.16). In the 31–40-year subgroup, the epilepsy group exhibited a higher asthma incidence than did the control group (10.73 versus 7.81 per 1,000 person-years; adjusted HR: 1.34, 95% CI: 1.12–1.61). By contrast, in the 11–20-year subgroup, the epilepsy group exhibited a lower asthma incidence than did the control group (7.92 versus 12.59 per 1,000 person-years; adjusted HR: 0.62, 95% CI: 0.51–0.75). In the >70-year subgroup, the epilepsy
group exhibited a lower asthma incidence than did the control group (21.36 versus 24.46 per 1,000 person-years; adjusted HR: 0.78, 95% CI: 0.69–0.87). In addition, the asthma and control groups both had lower subsequent incidence of epilepsy among patients in the highest household income bracket; among patients who lived in southern Taiwan, both groups also had lower subsequent incidence of epilepsy.

The Kaplan–Meier analysis revealed epilepsy to be positively associated with subsequent development of asthma within the first 7 years of epilepsy diagnosis. After 7 years, the results indicated a negative association (Fig. 3).
DISCUSSION

Our review of the relevant literature indicated the current study to be the first study to apply a longitudinal dataset to execute a two-way population-based retrospective analysis in order to evaluate the asthma risk among patients with epilepsy as well epilepsy risk among patients with asthma. Our results confirm our hypothesis stating that patients with asthma are more likely to develop epilepsy than are other individuals. In addition, female patients with asthma had a significantly higher risk of epilepsy than did male patients with asthma. By contrast, patients with epilepsy did not have a significantly increased risk of asthma compared with individuals without epilepsy. However, the Kaplan–Meier analysis revealed epilepsy to be positively associated with subsequent asthma development within the first 7 years of epilepsy diagnosis. Furthermore, patients diagnosed as having epilepsy at the ages of 0–10 and 31–40 years were indicated to be at an increased risk of asthma in later life, whereas those diagnosed at the ages of 11–20 and >70 years were indicated to be at a decreased risk of asthma in later life, compared with other individuals. Similar to the results of previous studies, the present study revealed that household income and geographic variation influenced incidence of asthma and epilepsy. Eastern Taiwan had a higher incidence of epilepsy than did other areas, and southern Taiwan had a lower incidence of asthma than did other areas. In addition, the population in the highest household income bracket had lower incidences of epilepsy and asthma than did those in all lower brackets.

This study observed a significant temporal association of asthma with epilepsy risk. Some clinical cases of epilepsy induced by long-standing asthma support our results (Costello & Fox, 1936; Czubkowska et al., 1994). A study involving the surveillance of epilepsy in 800 children with asthma reported that 26 children subsequently developed epilepsy and that asthmatic children exhibited a significantly higher epilepsy prevalence rate than did the general population.
(Bilan & Ghaffari, 2008). A U.S. population–based study (Silverberg, Joks & Durkin, 2014) that applied the 2007–2008 National Survey of Children’s Health showed that children having ≥1 allergy disease exhibited a higher frequency of epileptic episodes in their lifetime than did their nonallergic counterparts.

Our results revealed that patients with asthma are more prone to epilepsy, but not vice versa. The association between the two disorders may be primarily the result of the sequelae of asthma diagnosis. The most likely mechanism linking asthma to epilepsy development is anoxia due to frequent asthma attacks; however, we were unable to address this mechanism because the frequencies of asthma attacks and epileptic seizures could not be determined based on the current dataset. Another direct mechanism is hypocapnia. Hypocapnia, caused by hyperventilation, is commonly observed in patients with asthma (Bruton & Holgate, 2005), and it can induce vasoconstriction causing cerebral hypoperfusion, diminishing oxygen delivery, and increasing neuronal excitation by releasing glutamate and dopamine. Hyperventilation engenders interictal discharges, which are particularly relevant in idiopathic seizures. Hyperventilation-induced activation is significantly more frequent in the temporal lobe than in other lobes (Guaranha et al., 2005). Furthermore, hyperventilation induces absence seizures (Wirrell et al., 1996). Apart from hypocapnia, the most common finding in terms of acid–base disturbances in patients with acute asthma is respiratory alkalosis (Mountain et al., 1990). The hypoxic effect of hypocapnia can exaggerate respiratory alkalosis, resulting in a left shift of the hemoglobin–oxygen dissociation curve. Furthermore, metabolic acidosis is prevalent in patients having severe asthma. The ultimate outcomes of the aforementioned processes include reduced cerebral blood flow and oxygen transport and delivery to the brain. Additionally, alkalosis was reported to promote calcium binding to plasma albumin, resulting in a reduced serum level of ionized calcium.
(Locatto et al., 1984), which can increase the probability of seizures. Adding xanthine-containing antiasthmatic agents such as theophylline and aminophylline with potential central nervous system (CNS) stimulant properties may further complicate the management of epilepsy because of a lack of seizure control or precipitation of seizures in epileptic asthmatics. Theophylline-associated seizures are considered a neurological emergency because they can be intractable. Such seizures were reported in patients with low and therapeutic serum levels of theophylline, indicating that seizures are not merely a result of dose-dependent drug toxicity (Dunn & Parekh, 1991).

Our results revealed no significantly higher risk of asthma in patients with epilepsy than in individuals without epilepsy. Per our review of the relevant literature, no studies have determined whether epilepsy is a risk factor for asthma. However, we noted epilepsy to be positively associated with asthma development within the first 7 years of epilepsy diagnosis. In age subgroup analysis, patients diagnosed as having epilepsy aged 0–10 or 31–40 years were observed to have a high risk of asthma development in later life, whereas those diagnosed as having epilepsy aged 11–20 or >70 years were observed to have a low risk of asthma development in later life. Therefore, we believe that the epilepsy–asthma association is complicated and multifactorial. A Taiwanese study reported an asthma risk in children who experience febrile seizures; the findings of the study partially support our findings in the 0–10-year subgroup (Lin et al., 2014).

Chronic inflammation is a crucial mechanism in both asthma and epilepsy. The epilepsy–asthma association may be explained by several hypotheses. First, the two disorders perhaps share similar susceptible genes, including de novo mutations and cytokine genes. Moreover, cytokines oversecreted following a course of atopic reactions can pass through the blood–brain
barrier, subsequently contributing to neuroinflammation and damaging neuron cells. Mao et al. (2013) positively correlated interleukin (IL)-17a, IL-6, interferon (IFN)-γ, and IL-10 levels with the severity and frequency of seizures and suggested that the IL-17a level was correlated significantly with seizure frequency. Another study revealed the IL-6-174G>C (rs1800795) polymorphism to be significantly associated with the frequency of epileptic seizures and with the incidence of drug-refractory epilepsy (Tiwari et al., 2012). Elevated levels of IL-6 and IL-1b have been reported in patients with asthma, with the cytokines being particularly overexpressed in the asthmatic bronchial epithelium (Ishioka, 1996; Thomas & Chhabra, 2003; Martinez-Nunez et al., 2014); this thus signifies that these cytokines might play in role in mediating proinflammatory processes and airway hyperresponsiveness underlying asthmatic diseases. The chronic neuroinflammation and neuronal damage resulting from the penetration of cytokines through the blood–brain barrier raises patient susceptibility to epileptogenesis.

Second, specific viral infections and injury-associated proinflammatory cytokines can trigger asthma and epilepsy; fever-related inflammatory cytokines as well as bacterial, specific viral, and other pathogenic infections can also contribute to pathogenesis. Arteritis, ischemia, and infarction are the main pathological outcomes of severe viral or bacterial CNS diseases and may result in seizures (Sander, 2004). In addition, a mild infection may activate the IL-1 receptor–toll-like receptor pathway; however, damage-associated molecular patterns including high mobility group box 1 could engender such activation (van Vliet et al.). Specific viral infections, such as adenovirus, herpes simplex virus, human herpesvirus-6, influenza, and respiratory syncytial virus, were associated with febrile seizures (Lin et al., 2014). Rotavirus and norovirus enteritis are associated with benign convulsions in childhood (Kim et al., 2016; Yorulmaz, Sert & Yilmaz, 2017). Furthermore, brain inflammation can be induced by the cyclooxygenase-2-
induced production of prostaglandins (Fabene et al., 2008; Serrano et al., 2011). Additional bodies of evidence indicate that mast cells and microglial cells as well as their interaction substantially influence neuroinflammation (Chiou & Hsieh, 2008; Skaper, Facci & Giusti, 2014).

Channelopathies may partially contribute to comorbidities related to epilepsy and asthma. Channelopathies refer to diseases engendered by ion channel defects that are caused by genetic or acquired factors; ion-channel-encoding gene mutations are the most common cause of such diseases. Such defects have been implicated in an extensive range of disorders and conditions, which include migraine, epilepsy, deafness, blindness, diabetes, cardiac arrhythmia, hypertension, asthma, cancer, and irritable bowel syndrome. Absence epilepsy is reportedly associated with mutations in several ion-channel-encoding genes. For example, CACNA1H gene variants, denoting the α1H pore-forming subunit of T-type calcium channels, were observed in a patient subset diagnosed as having childhood absence epilepsy (CAE) (Chen et al., 2003). Scholars have additionally implicated missense GABRA1, GABRA6, GABRB3, and GABARG2 mutations—genes encoding numerous GABA-A receptor subunits—in CAE (Gurba et al., 2012; Kim, 2014; Spillane, Kullmann & Hanna, 2016). The onset of CAE is commonly in the age range of 4 to 10 years, peaking at 5–7 years. More than half of all patients with CAE enter remission in adolescence. Such characteristics of channelopathies could partially explain why in our cohort of patients with epilepsy, those who had experienced the onset of epilepsy while aged 0–10 years were indicated to be at a high risk of asthma development in later life, whereas those who had experienced it while aged 11–20 years were indicated to be a decreased risk.

Some antiepileptic drugs (AEDs) might play roles in preventing and reducing the frequency of asthma attacks. Studies have suggested that in addition to the suppression of inflammation and bronchodilation, the control of excitatory mechanisms including voltage-gated sodium channel
and glutamate receptors present in the brain and lung tissue, adjunctive glycine, and GABA agonists could facilitate the development of highly effective and safe asthma prevention and treatment strategies (Hoang et al., 2006; Hoang et al., 2010). Phenytoin was proven effective against acute and paroxysmal asthma, with most phenytoin-treated patients exhibiting sustained benefits even after treatment discontinuation (Shulman, 1942; Sayar & Polvan, 1968; Jain & Jain, 1991). Carbamazepine and sodium valproate have also been reported as having high antiasthmatic activities (Lomia et al., 2005). Lidocaine, a local anesthetic used in status epilepticus, works primarily by blocking sodium channels and decreasing membrane excitability. It was also effective in treating patients with severe steroid-dependent asthma (Slaton, Thomas & Mbathi, 2013). Our previous research showed that the AED prescription rate among children with epilepsy was lower than that among adolescents with epilepsy in Taiwan (Fig. 4) (Chiang & Cheng, 2014), and this could partially explain why in our epilepsy cohort of patients with epilepsy, those who had experienced the onset of epilepsy while aged 0–10 years were indicated to at a high risk of asthma development in later life, whereas those who had experienced it while aged 11–20 years were indicated to be at a decreased risk.

The insular cortex might be critical in the epilepsy–asthma association. Dyspnea is a high-impact symptom of asthma. A study noted that the periaqueductal gray matter downregulated affect-related insular cortex activity during sensations of pain and dyspnea in patients with asthma. The implicated insular cortex and periaqueductal gray matter might present as a mechanism of neuronal habituation, thereby ameliorating the corresponding unpleasantness of affective dyspnea in such patients (von Leupoldt et al., 2009). In another study, a group of patients with insular cortex lesions were indicated to experience reduced perceptual sensitivity to dyspnea unpleasantness, compared with the corresponding control group (Schon et al., 2008). By
contrast, some case reports have demonstrated that in patients with insular cortex epilepsy, a seizure attack could clinically present as dyspnea and chest tightness during sleep, and this could be difficult to distinguish from asthma-associated dyspnea.

Our study involves certain limitations that warrant consideration. First, in the claims data, the medical coding accuracy may influence data validity; this is because only people who sought medical aid were enlisted. In addition, diagnoses were based on inpatient claims and ambulatory care claims; hence, some may have represented a tentative diagnosis, rather than a final diagnosis. However, epilepsy is stigmatized in Taiwan, and thus identifying epilepsy in patients may be difficult in some cases. Although physicians apply the same diagnostic criteria, biases may be possible. However, the NHIA has a medical review system to monitor insurance claims; consequently, the effect of diagnostic validity on our findings is minimal. Second, the NHIRD limitations necessitated the use of only ICD-9-CM codes (i.e., 345 for epilepsy and 493 for asthma) for case patient identification. Further information such as syndromes, epilepsy classification, and asthma severity level was unavailable. Third, the NHIRD does not include medical record information on factors that might have exerted a minor influence on our results, such as the comorbidities of atopic dermatitis and allergic dermatitis, food allergies, family histories, personal lifestyles, and environmental factors. Fourth, the control group may have included patients with undiagnosed asthma or epilepsy. This sampling bias may be slightly overestimated in the control group but not sufficiently to affect the interpretation of the results. Finally, we did not analyze drug-related pathogenic or therapeutic effects such as the antiasthmatic effect of AEDs and epileptogenicity of xanthine-containing antiasthmatic agents.
CONCLUSION

Despite the limitations in this study, our data suggest a complex epilepsy–asthma association. Patients with asthma had a higher risk of epilepsy than did individuals without asthma. By contrast, risk of asthma did not differ significantly between patients with epilepsy and individuals without epilepsy. However, patients experiencing epilepsy onset at specific ages had a higher or lower risk of asthma development than did individuals without epilepsy. The results revealed that patients with asthma are more prone to epilepsy, but not vice versa. One of the most likely explanations of the association between asthma and epilepsy is anoxia due to frequent asthma attacks or due to the side effects of antiasthma medication. To effectively fill the knowledge gap, future studies are recommended to focus on incidence of epilepsy in patients with asthma of varying severity or in patients with varying levels of asthma control and compliance. Another possible explanation for the association between these two disorders is that they share common pathogenic mechanisms, which include hypocapnia, chronic inflammation, immune dysregulation, genetic susceptibility, channelopathies, drug-related pathogenic or therapeutic effects, and environmental factors. Additional studies should be conducted on these hypotheses to elucidate the mechanisms that link asthma, atopic dermatitis, or a broader atopy spectrum to epilepsy. In addition, our findings contributed to the literature on socioeconomic disparity, including the influence of household income and geographic variation on patients with epilepsy and those with asthma; physicians and public health policymakers should focus on this aspect. Reducing such disparity requires interventions to prevent epilepsy and asthma and improve the quality of care for these disorders.
Acknowledgments

The authors thank the NHRI and the NHIA for providing the study data. This manuscript was edited by Wallace Academic Editing.
REFERENCES

Abramson HA. 1978. Asthma, epilepsy and allergy. Journal of Asthma Research 15:159-162.

Bilan N, Ghaffari S. 2008. Association of asthma and epilepsy. Research Journal of Biological Sciences 3:1370-1372.

Browne TR, Holmes GL. 2001. Epilepsy. New England Journal of Medicine 344:1145-1151. DOI: 10.1056/NEJM200104123441507.

Brumpton BM, Leivseth L, Romundstad PR, Langhammer A, Chen Y, Camargo CA JR, Mai XM. 2013. The joint association of anxiety, depression and obesity with incident asthma in adults: the hunt study. International Journal of Epidemiology 42:1455-1463.

Bruton A, Holgate ST. 2005. Hypocapnia and asthma: a mechanism for breathing retraining? Chest 127:1808-1811. DOI: 10.1093/ije/dyt151.

Carvajal-Uruena I, Garcia-Marcos L., Busquets-Monge R, Morales Suarez-Varela M, Garcia de Andoin N, Batlles-Garrido J., Blanco-Quiros A, Lopez-Silvarrey A, Garcia-Herandez G, Guillen-Grimaj F, Gonzalez-Diaz C, Bellido-Blasco J. 2005. Geographic variation in the prevalence of asthma symptoms in Spanish children and adolescents. International Study of Asthma and Allergies in Childhood (ISAAC) Phase 3, Spain. Archivos de bronconeumologia 41:659-666.

Castaneda GY, Heilbroner PL, Shah N, Forem S, Fish I. 1998. Asthma and epilepsy: are they related? a retrospective study. Journal of Child Neurology 13:283-285. DOI: 10.1177/088307389801300608.
Chang BS, Lowenstein DH. 2003. Epilepsy. New England Journal of Medicine 349:1257-1266. DOI: 10.1056/NEJMra022308.

Chen CC, Chen LS, Yen MF, Chen HH, Liou HH. 2012. Geographic variation in the age- and gender-specific prevalence and incidence of epilepsy: analysis of Taiwanese national health insurance-based data. Epilepsia 53:283-290. DOI: 10.1111/j.1528-1167.2011.03332.x.

Chen Y, Lu J, Pan H, Zhang Y, Wu H, Xu K, Liu X, Jiang Y, Bao X, Yao Z, Ding K, Lo W H, Qiang B, Chan P, Shen Y, Wu X. 2003. Association between genetic variation of cacna1h and childhood absence epilepsy. Annals of Neurology 54:239-243.

Chiang KL, Chang KP, Wong TT, Hsu TR. 2009a. Linear scleroderma "en coup de sabre": initial presentation as intractable partial seizures in a child. Pediatrics & Neonatology 50:294-298.

Chiang KL, Cheng CY. 2014. Prevalence and neuro-psychiatric comorbidities of pediatric epilepsy in Taiwan: a national population-based study. Epilepsy Research 108:1451-1460.

Chiang KL, Wong TT, Kwan SY, Hsu TR, Wang CH, Chang KP. 2009b. Finding on brain MRI mimicking focal cortical dysplasia in early Rasmussen's encephalitis: a case report and review. Child's Nervous System 25:1501-1506.

Chie WC, Chen CF, Chen CJ, Chang CL, Liaw YP, Lin RS. 1995. Geographic variation of breast cancer in Taiwan: international and migrant comparison. Anticancer Research 15:2745-2749.

Chien IC, Lin CH, Chou YJ, Chou P. 2012. Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national population-based
study. *Social Psychiatry and Psychiatric Epidemiology* 47:1885-1890.

Chiou HH, Hsieh LP. 2008. Parenting stress in parents of children with epilepsy and asthma. *Journal of Child Neurology* 23:301-306.

Choi S, Kim SH, Lee JS. 2017. Association between depression and asthma in korean adults. *Allergy & Asthma Proceedings* 38:238-239.

Cinca I, Dimitriu R. 1976. Clinical and electroencephalographic study of allergic epilepsy. *Revista de Medicina Interna, Neurologie, Psihiatrie, Neurochirurgie, Dermato-Venerologie, Neurologie, Psihiatrie, Neurochirurgie* 21:215-224.

Costello K, Fox JT. 1936. A case showing an unusual relationship between asthma and epilepsy. *Lancet* 1:660.

Czubkowska I, Karkowska B, Najberg E, Zychowicz C, Nowacka K. 1994. Epilepsy as a complication of bronchial asthma. *Polski Tygodnik Lekarski* 49:448-450.

Devinsky O, Schein A, Najjar S. 2013. Epilepsy associated with systemic autoimmune disorders. *Epilepsy Currents* 13:62-68.

Dunn DW, Parekh HU. 1991. Theophylline and status epilepticus in children. *Neuropediatrics* 22:24-26.

Elliott JO, Moore JL, Lu B. 2008. Health status and behavioral risk factors among persons with epilepsy in ohio based on the 2006 behavioral risk factor surveillance system. *Epilepsy & Behavior* 12:434-444.

England MJ, Liverman CT, Schultz AM, Strawbridge LM. 2012. Epilepsy across the spectrum:
promoting health and understanding. A summary of the institute of medicine report. 

*Epilepsy & Behavior* 25:266-276.

Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo F, Ottoboni L, Bach S, Angiari S, Benati D, Chakir A, Zanetti L, Schio F, Osculati A, Marzola P, Nicolato E, Homeister JW, Xia L, Lowe JB, Mcever RP, Osculati F, Sbarbati A, Butcher EC, Constantin G. 2008. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. *Nature Medicine* 14:1377-1383.

Fasmer OB, Halmoy A, Eagan TM, Oedegaard KJ, Haavik J. 2011. Adult attention deficit hyperactivity disorder is associated with asthma. *BMC Psychiatry* 11:128.

Feigin VL, Abajobir AA, Abate KH, Abd-Allah F, Abdulle AM, Abera SF, Abyu GY, Ahmed MB, Aichour AN, Aichour I. 2017. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet Neurology* 16:877-897. DOI: 10.1016/S1474-4422(17)30299-5.

Fein BT, Kamin PB. 1968. Allergy, convulsive disorders and epilepsy. *Annals of Allergy, Asthma & Immunology* 26:241-247.

Forman J. 1934. Atopy as a cause of epilepsy. *Archives of Neurology and Psychiatry* 32(3):517-522.

Guaranha MS, Garzon E, Buchpiguel CA, Tazima S, Yacubian EM, sakamoto AC. 2005. Hyperventilation revisited: physiological effects and efficacy on focal seizure activation in the era of video-eeg monitoring. *Epilepsia* 46:69-75.
Gurba KN, Hernandez CC, Hu N, Macdonald RL. 2012. Gabrb3 mutation, g32r, associated with childhood absence epilepsy alters alpha1beta3gamma2l gamma-aminobutyric acid type a (gabaa) receptor expression and channel gating. *Journal of Biological Chemistry* 287:12083-12097.

Heaney DC, Macdonald BK, Everitt A, Stevenson S, Leonardi GS, Wilkinson P, Sander JW. 2002. Socioeconomic variation in incidence of epilepsy: prospective community based study in south east England. *BMJ* 325:1013-1016. DOI: 10.1136/bmj.325.7371.1013.

Hoang BX, Levine SA, Shaw DG, Pham P, Hoang C. 2006. Bronchial epilepsy or broncho-pulmonary hyper-excitability as a model of asthma pathogenesis. *Medical Hypotheses* 67:1042-1051.

Hoang BX, Shaw DG, Pham P, Levine SA. 2010. Treating asthma as a neuroelectrical disorder. *Inflammation & Allergy-Drug Targets* 9:130-134.

Hwang CY, Chen YJ, Lin MW, Chen TJ, Chu SY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. 2010. Prevalence of atopic dermatitis, allergic rhinitis and asthma in Taiwan: a national study 2000 to 2007. *Acta dermato-venereologica* 90:589-594. DOI: 10.2340/00015555-0963.

Ishioka S. 1996. Role of cytokines in pathophysiology of asthma. *Nihon Naika Gakkai Zasshi* 85:184-188.

Jain S, Jain KC. 1991. Effect of phenytoin sodium in the management of poorly controlled bronchial asthma at a rural health center in phalodi, rajasthan, India. *Journal of Asthma* 28:201-211.
Kaiboriboon K, Bakaki PM, Lhatoo SD, Koroukian S. 2013. Incidence and prevalence of treated epilepsy among poor health and low-income Americans. *Neurology* 80:1942-1949. DOI: 10.1212/WNL.0b013e318293e1b4.

Kim GH, Byeon JH, Lee DY, Jeong HJ, Eun BL. 2016. Norovirus in benign convulsions with mild gastroenteritis. *Italian Journal of Pediatrics* 42:94.

Kim JB. 2014. Channelopathies. *Korean Journal of Pediatrics* 57:1-18.

Kobau R, Diiorio CA, Price PH, Thurman DJ, Martin LM, Ridings DL, Henry TR. 2004. Prevalence of epilepsy and health status of adults with epilepsy in georgia and tennessee: behavioral risk factor surveillance system, 2002. *Epilepsy & Behavior* 5:358-366.

Levin SJ. 1931. Allergic epilepsy. *Journal of the American Medical Association* 97:1624.

Lin WY, Muo CH, Ku YC, Sung FC, Kao CH. 2014. Risk of subsequent asthma in children with febrile seizures: a nationwide population-based retrospective cohort study. *Pediatric Neurology* 51:795-799.

Locatto ME, Fernandez MC, Cafera DA, Gimenez MC, Vidal MC, Puche RC. 1984. Respiratory alkalosis and reduced plasmatic concentration of ionized calcium in rats treated with 1,25 dihydroxycholecalciferol. *Calcified Tissue International* 36:604-607.

Lomia M, Chapichadze Z, Pruidze M, Platonov P. 2005. Efficacy of monotherapy with carbamazepine and valproic acid in patients with bronchial asthma: is asthma a neurological disease. *Internet Journal of Neurology* 4:1-4.

Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee C M,
Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH. 2006. Secular trends and geographic variations of hepatitis b virus and hepatitis c virus-associated hepatocellular carcinoma in taiwan. *International Journal of Cancer* 119:1946-1952.

Malhotra K, Baltrus P, Zhang S, Mcroy L, Immergluck LC, Rust G. 2014. Geographic and racial variation in asthma prevalence and emergency department use among Medicaid-enrolled children in 14 southern states. *The Journal of asthma* 51:913-921. DOI: 10.3109/02770903.2014.930479.

Mao LY, Ding J, Peng WF, Ma Y, Zhang YH, Fan W, Wang X. 2013. Interictal interleukin-17a levels are elevated and correlate with seizure severity of epilepsy patients. *Epilepsia* 54:e142-e145.

Markus AR., Lyon M. & Rosenbaum SJ. 2010. Changing policy: The elements for improving childhood asthma outcomes. Washington, DC: Department of Health Policy, the George Washington University School of Public Health and Health Services.

Martinez-Nunez RT, Bondanese VP, Louafi F, Francisco-Garcia AS, Rupani H, Bedke N, Holgate S, Howarth PH, Davies DE, Sanchez-Elsner T. 2014. A microrna network dysregulated in asthma controls il-6 production in bronchial epithelial cells. *Plos One* 9:e111659. DOI: 10.1371/journal.pone.0111659.

Masoli M, Fabian D, Holt S, Beasley R. 2004. The global burden of asthma: executive summary of the gina dissemination committee report. *Allergy* 59:469-478.

Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, Scalia MR, Akinbami LJ. 2007. National surveillance for asthma--united states, 1980-2004. *MMWR*
Surveillance Summaries 56:1-54.

Mountain RD, Heffner JE, Brackett NC JR, Sahn SA. 1990. Acid-base disturbances in acute asthma. Chest 98:651-655.

Mysik M, Czerniawska-Mysik G. 1972. Allergic reactions and epilepsy attacks. Przeglad Lekarski 29:325-330.

Nunes C, Pereira AM, Morais-Almeida M. 2017. Asthma costs and social impact. Asthma Research and Practice 3:1. DOI: 10.1186/s40733-016-0029-3.

Oh S, Ji H, Barzman D, Lin PI, Hutton J. 2015. Pediatric asthma and autism-genomic perspectives. Clinical and Translational Medicine 4:37. DOI: 10.1186/s40169-015-0078-x.

Olin JT, Wechsler ME. 2014. Asthma: pathogenesis and novel drugs for treatment. BMJ 349:g5517. DOI: 10.1136/bmj.g5517.

Pallin DJ, Goldstein JN, Moussally JS, Pelletier AJ, Green AR, Camargo CA JR. 2008. Seizure visits in us emergency departments: epidemiology and potential disparities in care. International Journal of Emergency Medicine 1:97-105.

Pawankar R. 2014. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organization Journal 7:12. DOI: 10.1186/1939-4551-7-12.

Ray, NF, Thamer, M, Fadillioglu B, Gergen PJ. 1998. Race, income, urbanicity, and asthma hospitalization in California: a small area analysis. Chest 113:1277-1284. DOI: 10.1378/chest.113.5.1277.

Sander JW. 2004. Infectious agents and epilepsy. National Academies Press (US).
Sayar B, Polvan O. 1968. Epilepsy and bronchial asthma. *Lancet* 1:1038.

Schon D, Rosenkranz M, Regelsberger J, Dahme B, Buchel C, Von Leupoldt A. 2008. Reduced perception of dyspnea and pain after right insular cortex lesions. *American Journal of Respiratory and Critical Care Medicine* 178:1173-1179.

Serrano GE, Lelutiu N, Rojas A, Cochi S, Shaw R, Makinson CD, Wang D, Fitzgerald G A, Dingledine R. 2011. Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. *Journal of Neuroscience* 31:14850-14860.

Shulman MH. 1942. The use of dilantin sodium in bronchial asthma: a preliminary report. *New England Journal of Medicine* 226:260-264.

Silverberg JI, Joks R, Durkin HG. 2014. Allergic disease is associated with epilepsy in childhood: a us population-based study. *Allergy* 69:95-103.

Skaper SD, Facci L, Giusti P. 2014. Mast cells, glia and neuroinflammation: partners in crime? *Immunology* 141:314-327.

Slaton RM, Thomas RH, Mbathi JW. 2013. Evidence for therapeutic uses of nebulized lidocaine in the treatment of intractable cough and asthma. *Annals of Pharmacotherapy* 47:578-585.

Soriano JB, Ababajir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, Aichour AN, Aichour I, Aichour MTE, ALAM K. 2017. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of
Disease Study 2015. *The Lancet Respiratory Medicine* 5:691-706. DOI: 10.1016/S2213-2600(17)30293-X.

Speer F. 1967. Neurologic allergy: the problem of classification. *Annals of Allergy, Asthma & Immunology* 25:421-425.

Spillane J, Kullmann DM, Hanna MG. 2016. Genetic neurological channelopathies: molecular genetics and clinical phenotypes. *The Journal of Neurology, Neurosurgery, & Psychiatry* 87:37-48.

Strine TW, Kobau R, Chapman DP, Thurman DJ, Price P, Balluz LS. 2005. Psychological distress, comorbidities, and health behaviors among U.S. Adults with seizures: results from the 2002 national health interview survey. *Epilepsia* 46:1133-1139.

Stump E. 2008. Hospital admissions for epilepsy and convulsions increase nationwide. *Neurology today* 8. DOI: 10.1097/01.nt.0000314455.74483.e0, 113.

Thomas SS, Chhabra SK. 2003. A study on the serum levels of interleukin-1beta in bronchial asthma. *Journal of Indian Medical Association* 101, 282, 284, 286 passim.

Tiwari P, Dwivedi R, Mansoori N, Alam R, Chauhan UK, Tripathi M, Mukhopadhyay AK. 2012. Do gene polymorphism in il-1beta, tnf-alpha and il-6 influence therapeutic response in patients with drug refractory epilepsy? *Epilepsy Research* 101:261-267.

Van Lieshout RJ, Macqueen GM. 2012. Relations between asthma and psychological distress: an old idea revisited. *Chemical Immunology and Allergy* 98:1-13.

Van Vliet EA, Aronica E, Vezzani A, Ravizza T. 2017. Neuroinflammatory pathways as
treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies. *Neuropathology and Applied Neurobiology* DOI:10.1111/nan.12444.

Vincent A, Crino PB. 2011. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. *Epilepsia* 52(3):12-17.

Von Leupoldt A, Sommer T, Kegat S, Eippert F, Baumann HJ, Klose H, Dahme B, Buchel C. 2009. Down-regulation of insular cortex responses to dyspnea and pain in asthma. *American Journal of Respiratory and Critical Care Medicine* 180:232-238.

Wang J, Wang Y, Wang LB, Xu H Zhang XL. 2012. A comparison of quality of life in adolescents with epilepsy or asthma using the short-form health survey (sf-36). *Epilepsy Research* 101:157-165.

Wirrell EC, Camfield PR, Gordon KE, Camfield CS, Dooley JM, Hanna BD. 1996. Will a critical level of hyperventilation-induced hypocapnia always induce an absence seizure? *Epilepsia* 37:459-462.

Yorulmaz A, Sert S, Yilmaz FH. 2017. Evaluation of benign afebrile convulsions in 16 children with rotavirus gastroenteritis. *Acta Neurologica Belgica* 117:441-445.

Zheng Z, Zhang L, Zhu T, Huang J, Qu Y, Mu D. 2016. Association between asthma and autism spectrum disorder: a meta-analysis. *Plos One* 11:e0156662.
FIGURE CAPTIONS

Figure 1 Flowchart of study patient selection.

Figure 2 Survival curve of epilepsy development among patients with asthma and the control group.

Figure 3 Survival curve of asthma development among patients with epilepsy and the control group.

Figure 4 Prevalence of epilepsy and epilepsy with AED prescription. (Data reference: Chiang & Cheng, 2014)
**Table 1** (on next page)

Demographic characteristics of patients with asthma and controls.
Table 1 Demographic characteristics of patients with asthma and controls.

| Characteristic  | Nonasthma comparison group | Patients with asthma | p-value |
|-----------------|-----------------------------|----------------------|---------|
|                 | n=150827 percentile         | n=150827 percentile  |         |
| Age (years)     |                             |                      |         |
| 0-10            | 47394 31.42%                | 47394 31.42%         |         |
| 11-20           | 11885 7.88%                 | 11885 7.88%          |         |
| 21-30           | 13044 8.65%                 | 13044 8.65%          |         |
| 31-40           | 16530 10.96%                | 16530 10.96%         |         |
| 41-50           | 17076 11.32%                | 17076 11.32%         |         |
| 51-60           | 16214 10.75%                | 16214 10.75%         |         |
| 61-70           | 14640 9.71%                 | 14640 9.71%          |         |
| >70             | 14034 9.30%                 | 14034 9.30%          |         |
| Mean (SD) of Age| 33.41 (25.51)               | 33.41 (25.51)        | 1.00*   |
| Sex             |                             |                      |         |
| Female          | 76998 51.05%                | 76998 51.05%         |         |
| Male            | 73819 48.94%                | 73819 48.94%         | 1.00**  |
| Income          |                             |                      |         |
| 0               | 69082 45.80%                | 70137 46.50%         |         |
| <20000          | 28711 19.04%                | 27032 17.92%         |         |
| 20000-39999     | 38688 25.65%                | 39128 25.94%         |         |
| >40000          | 14336 9.50%                 | 14520 9.63%          | < 1.964e-13* |
| Residence location |                         |                      |         |
| North           | 68234 45.24%                | 78449 52.01%         |         |
| Central         | 37455 24.83%                | 35953 23.84%         |         |
| South           | 40592 26.91%                | 31785 21.07%         |         |
| East            | 3505 2.32%                  | 3715 2.46%           |         |
| Off island      | 1031 0.68%                  | 915 0.61%            | < 2.2e-16* |

*p-value was calculated by Chi-square statistic.

**p-value was calculated by t statistic.
Table 2 (on next page)

HRs for incidence of epilepsy in relation to asthma.
|                | No asthma comparison Group | Patient with asthma | Hazard ratio and 95% CI (patient with asthma vs. comparison group) |
|----------------|-----------------------------|---------------------|------------------------------------------------------------------|
|                | Case s PY Incidencea        | Cases PY Incidencea | Unadjusted Adjustedb                                             |
| ALL            | 3264 1446014 2.26           | 4236 1386893 3.05   | 1.35* (1.29—1.41) 1.39* (1.33—1.45)                              |
| Stratified by SEX |                             |                     |                                                                 |
| Female         | 1482 726276 2.04            | 2079 694427 2.99    | 1.47* (1.37—1.57) 1.52* (1.42—1.64)                              |
| Male           | 1782 719738 2.48            | 2157 692466 3.12    | 1.25* (1.18—1.33) 1.28* (1.21—1.37)                              |
| Stratified by AGE |                             |                     |                                                                 |
| 0-10           | 878 471260 1.86             | 1141 488971 2.33    | 1.27* (1.16—1.38) ---                                           |
| 11-20          | 184 125089 1.47             | 178 113217 1.57     | 1.05 (0.85—1.29) ---                                           |
| 21-30          | 140 112963 1.24             | 173 111653 1.55     | 1.26* (1.01—1.57) ---                                           |
| 31-40          | 191 143218 1.33             | 296 140908 2.10     | 1.57* (1.31—1.89) ---                                           |
| 41-50          | 249 153727 1.62             | 418 151436 2.76     | 1.71* (1.46—1.99) ---                                           |
| 51-60          | 359 148633 2.42             | 495 134844 3.67     | 1.52* (1.33—1.74) ---                                           |
| 61-70          | 541 142983 3.78             | 732 130915 5.59     | 1.48* (1.33—1.66) ---                                           |
| >70            | 722 148142 4.88             | 803 114948 6.99     | 1.39* (1.26—1.54) ---                                           |
| Stratified by INCOME |                             |                     |                                                                 |
| 0              | 1614 677069 2.38            | 1981 660961 3.00    | 1.25* (1.17—1.33) ---                                           |
| <20000         | 784 278760 2.81             | 1011 253786 3.98    | 1.41* (1.28—1.55) ---                                           |
| 20000-39999    | 744 362018 2.06             | 1073 347930 3.08    | 1.50* (1.37—1.65) ---                                           |
| >40000         | 122 128167 0.95             | 171 124216 1.38     | 1.46* (1.15—1.84) ---                                           |
| Stratified by LOCATION |                         |                     |                                                                 |
| N              | 1385 650132 2.13            | 1885 713899 2.64    | 1.23* (1.15—1.32) ---                                           |
| C              | 958 360406 2.66             | 1230 335659 3.66    | 1.38* (1.27—1.50) ---                                           |
| S              | 802 391822 2.05             | 953 295787 3.22     | 1.57* (1.43—1.73) ---                                           |
| E              | 97 33574 2.89               | 139 33990 4.09      | 1.41* (1.08—1.82) ---                                           |
| O              | 22 10081 2.18               | 29 7558 3.84        | 1.71 (0.98–2.97) ---                                            |

2 PY: person-years at risk
3 a The incidence is per 1000 person-year
4 b Adjusted for age, sex, income and residence location
5 * Significance at 0.05 level
Table 3 (on next page)

Demographic characteristics of patients with epilepsy and controls.
Table 3 Demographic characteristics of patients with epilepsy and controls.

| Characteristic | Nonepilepsy comparison group | Patients with epilepsy | p-value |
|----------------|------------------------------|------------------------|---------|
|                | n=25274 | percentile | n=25274 | percentile |         |
| Age (years)    |         |            |         |            |         |
| 0-10           | 5122    | 20.27%     | 5122    | 20.27%     |         |
| 11-20          | 2326    | 9.20%      | 2326    | 9.20%      |         |
| 21-30          | 2515    | 9.95%      | 2515    | 9.95%      |         |
| 31-40          | 2798    | 11.07%     | 2798    | 11.07%     |         |
| 41-50          | 3231    | 12.78%     | 3231    | 12.78%     |         |
| 51-60          | 3010    | 11.91%     | 3010    | 11.91%     |         |
| 61-70          | 2688    | 10.64%     | 2688    | 10.64%     |         |
| >70            | 3584    | 14.18%     | 3584    | 14.18%     |         |
| Mean (SD) of Age | 39.13 (25.92) | 39.13 (25.92) | 1.00* |

Sex
- Female | 11499 | 45.50% | 11499 | 45.50% | 1.00** |
- Male   | 13775 | 54.50% | 13775 | 54.50% |         |

Income
- 0      | 9715  | 38.44% | 10313 | 40.80% |         |
- <20000 | 5215  | 20.63% | 6707  | 26.54% |         |
- 20000-39999 | 7469 | 29.55% | 6597  | 26.10% |         |
- >40000 | 2875  | 11.38% | 1657  | 6.56%  | <2.2e-16* |

Residence location
- North | 10815 | 42.79% | 11447 | 45.29% |         |
- Central | 7148  | 28.28% | 6329  | 25.04% |         |
- South  | 6306  | 24.95% | 6665  | 26.37% |         |
- East   | 818   | 3.24%  | 644   | 2.55%  |         |
- Off island | 187  | 0.74%  | 189   | 0.75%  | <2.2e-16* |

*p-value was calculated by Chi-square statistic.

**p-value was calculated by t statistic.
Table 4 (on next page)

HRs for incidence of asthma in relation to epilepsy.
Table 4 HRs for incidence of asthma in relation to epilepsy.

| Hazard ratios for incidence of asthma in relation to epilepsy | No epilepsy comparison Group | Patient with epilepsy | Hazard ratio and 95% CI (patient with Epilepsy vs. comparison group) |
|---------------------------------------------------------------|-----------------------------|-----------------------|---------------------------------------------------------------------|
|                                                                 | Cases  | PY     | Incidence<sup>a</sup> | Cases  | PY     | Incidence<sup>a</sup> | Unadjusted | Adjusted<sup>b</sup> |
| ALL                                                           | 4235   | 238577 | 17.75                | 3752   | 199639 | 18.79                | 1.00 (0.96 — 1.04) | 0.96* (0.91 — 0.999) |
| Stratified by SEX                                             |        |        |                      |        |        |                      |            |                    |
| Female                                                        | 1866   | 106319 | 17.55                | 1712   | 90654  | 18.89                | 1.03 (0.96 — 1.10) | 1.02 (0.95 — 1.08) |
| Male                                                          | 2369   | 132259 | 17.91                | 2040   | 108984 | 18.72                | 0.97 (0.92 — 1.03) | 0.91* (0.86 — 0.97) |
| Stratified by AGE                                             |        |        |                      |        |        |                      |            |                    |
| 0-10                                                          | 1561   | 46110  | 33.85                | 1691   | 46423  | 36.43                | 1.09* (1.01 — 1.16) |   —                     |
| 11-20                                                         | 287    | 22799  | 12.59                | 174    | 21970  | 7.92                 | 0.62* (0.51 — 0.75) |   —                     |
| 21-30                                                         | 206    | 25423  | 8.10                 | 193    | 22582  | 8.55                 | 1.04 (0.86 — 1.27)  |   —                     |
| 31-40                                                         | 216    | 27674  | 7.81                 | 255    | 23773  | 10.73                | 1.34* (1.12 — 1.61) |   —                     |
| 41-50                                                         | 325    | 30930  | 10.51                | 305    | 25436  | 11.99                | 1.11 (0.94 — 1.29)  |   —                     |
| 51-60                                                         | 379    | 27604  | 13.73                | 301    | 20265  | 14.85                | 1.05 (0.90 — 1.22)  |   —                     |
| 61-70                                                         | 446    | 24722  | 18.04                | 385    | 18213  | 21.14                | 1.12 (0.98 — 1.29)  |   —                     |
| >70                                                           | 815    | 33316  | 24.46                | 448    | 20976  | 21.36                | 0.78* (0.69 — 0.87)  |   —                     |
| Stratified by INCOME                                          |        |        |                      |        |        |                      |            |                    |
| 0                                                             | 2256   | 87760  | 25.71                | 2163   | 80812  | 26.77                | 0.98 (0.93 — 1.04)  |   —                     |
| <20000                                                        | 796    | 51479  | 15.46                | 811    | 54368  | 14.92                | 0.91 (0.82 — 1.00)  |   —                     |
| 20000-39999                                                   | 943    | 72524  | 13.00                | 665    | 51268  | 12.97                | 0.97 (0.88 — 1.07)  |   —                     |
| >40000                                                       | 258    | 26858  | 9.61                 | 132    | 13241  | 9.97                 | 1.02 (0.825 — 1.26) |   —                     |
| Stratified by LOCATION                                        |        |        |                      |        |        |                      |            |                    |
| N                                                             | 2082   | 106545 | 19.54                | 1815   | 86230  | 21.05                | 1.02 (0.96 — 1.09)  |   —                     |
| C                                                             | 1047   | 59993  | 17.45                | 1056   | 55292  | 19.10                | 1.03 (0.95 — 1.12)  |   —                     |
| S                                                             | 958    | 64373  | 14.88                | 744    | 49795  | 14.94                | 0.94 (0.85 — 1.03)  |   —                     |
| E                                                             | 113    | 5852   | 19.31                | 113    | 6660   | 16.97                | 0.85 (0.66 — 1.11)  |   —                     |
| O                                                             | 35     | 1815   | 19.29                | 24     | 1662   | 14.44                | 0.74 (0.44 — 1.25)  |   —                     |

PY: person-years at risk

<sup>a</sup> The incidence is per 1000 person-year

<sup>b</sup> Adjusted for age, sex, income and residence location

* Significance at 0.05 level
Figure 1

Flowchart of study patient selection.
Figure 2

Survival curve of epilepsy development among patients with asthma and the control group.
Figure 3

Survival curve of asthma development among patients with epilepsy and the control group.
Figure 4

Prevalence of epilepsy and epilepsy with AEDs prescription. (Data reference: Chiang & Cheng, 2014)